GlassScriptPhysician profile
Erin Sperry Schlueter
NPI 1023306479
$3,311.87
in general payments reported to CMS, 2019-2025
27 companies · $495 in 2025
The $495 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $543 · 2020: $158 · 2021: $475 · 2022: $453 · 2023: $635 · 2024: $553 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,683.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $506.89 | 2019-2023 | Lo Loestrin Fe |
| Hologic Sales and Service, LLC | $466.96 | 2019-2025 | Acessa Provu System, Myosure Tissue Removal Device, Novasure |
| Organon LLC | $284.66 | 2022-2025 | Nexplanon, Nuvaring |
| Merck Sharp & Dohme LLC | $256.25 | 2019-2024 | Gardasil 9, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $247.65 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $230.99 | 2023-2025 | Myfembree |
| Astellas Pharma US INC | $229.07 | 2023-2025 | Veozah, Myrbetriq |
| Allergan, INC. | $146.97 | 2019 | |
| Myovant Sciences INC. | $115.43 | 2021-2022 | |
| Pfizer INC. | $111.86 | 2019-2025 | |
| Biogen, INC. | $110.06 | 2025 | Zurzuvae |
| Exeltis, USA INC. | $92.60 | 2019-2023 | Slynd |
| Therapeuticsmd, INC. | $65.21 | 2021 | |
| Gynesonics, INC. | $54.51 | 2023-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Mayne Pharma Commercial LLC | $54.19 | 2021-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $52.21 | 2024 | Paragard T 380a |
| Millicent US INC | $49.23 | 2020-2024 | Femring, Intrarosa |
| Myriad Women'S Health, INC. | $47.75 | 2023 | Myrisk |
| Intuitive Surgical, INC. | $40.00 | 2019 | |
| Amag Pharmaceuticals, INC. | $23.99 | 2020 | |
| Medtronic, INC. | $22.48 | 2022 | |
| Daiichi Sankyo INC. | $22.16 | 2019 | |
| Becton, Dickinson and Company | $21.00 | 2024 | Bd Onclarity |
| Aspira Women'S Health INC | $16.56 | 2020 | |
| Sage Therapeutics, LLC | $15.30 | 2019 | |
| Lupin INC. | $14.34 | 2021 | |
| Avanos Medical | $13.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Sperry Schlueter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.